Showing results (321-330 of 355) with videos related to

Sort By:
Pageof 36
The Lancet. Haematology|March 25, 2017
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trialRuben A Mesa, Alessandro M Vannucchi, Adam Mead, et al.
Forensic Science International. Genetics|May 22, 2016
Inter-laboratory evaluation of the EUROFORGEN Global ancestry-informative SNP panel by massively parallel sequencing using the Ion PGM™M Eduardoff, T E Gross, C Santos, et al.
International Journal of Hematology|August 9, 2019
Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patientsSzilvia Lovas, Gergely Varga, Péter Farkas, et al.
Future Oncology (London, England)|January 11, 2021
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemicSrdan Verstovsek, Chih-Cheng Chen, Miklós Egyed, et al.
Scientific Reports|November 18, 2024
Digital PCR-based quantification of miR-181a in the cerebrospinal fluid aids patient stratification in pediatric acute lymphoblastic leukemiaBorbála Péterffy, Tamás J Nádasi, Szilvia Krizsán, et al.
Leukemia|May 27, 2017
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blastsG Garcia-Manero, M A Sekeres, M Egyed, et al.
British Journal of Pharmacology|September 11, 2024
Progress on the development of Class A GPCR-biased ligandsPaula Morales, Magdalena M Scharf, Marcel Bermudez, et al.
Orvosi Hetilap|April 10, 2021
Diagnosis and treatment of paediatric multisystem inflammatory syndromeTamás Constantin, Noémi Andrási, Andrea Ponyi, et al.
The Lancet. Oncology|February 1, 2017
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trialAndrew D Zelenetz, Jacqueline C Barrientos, Jennifer R Brown, et al.
Leukemia Research|January 7, 2018
Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasmsAmbrus Gángó, Réka Mózes, Zsófia Boha, et al.
Pageof 36